Effect of SILA-409, a new organosilicon multidrug resistance modifier, on human pancreatic cancer xenografts

In Vivo

Volumn 20, Issue 1, 2006, Pages 137-140

  Zalatnai, Attila ^a   Molnár, József ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Multidrug resistance modifier; Organosilicon compound; P glycoprotein; Pancreatic cancer; Xenograft

Indexed keywords

1,3 DIMETHYL 1,3 BIS(4 FLUOROPHENYL) 1,3 BIS(3 MORPHOLINOPROPYL)DISILOXANE; ANTINEOPLASTIC AGENT; GLYCOPROTEIN P; MONOCLONAL ANTIBODY; ORGANOSILICON DERIVATIVE; SILA 409; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPSY; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MITOSIS RATE; MORPHOMETRICS; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PANCREAS CANCER; PANCREAS CARCINOMA; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 30844438507     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Longley DB and Johnston PG: Molecular mechanisms of drug resistance. J Pathol 205: 275-292, 2005.
2. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM and Pastan I: Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84: 265-269, 1987.
3. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, Lieber M, Cossman J, Gottesman MM and Pastan I: Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81: 116-124, 1989.
4. Gottesman MM: How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award lecture. Cancer Res 53: 747-754, 1993.
5. Leonard GD, Fojo T and Bates SE: The role of ABC transporters in clinical practice. Oncologist 8: 411-424, 2003.
6. Carmichael J: Clinical response benefit in patients with advanced pancreatic cancer. Role of gemcitabine. Digestion 58: 503-507, 1997.
7. Heinemann V: Gemcitabine: progress in the treatment of pancreatic cancer. Oncology 60: 8-18, 2001.
8. Suwa H, Ohshio G, Arao S, Imamura T, Yamaki K, Manabe T, Imamura M, Hiai H and Fukumoto M: Immunohistochemical localization of P-glycoprotein and expression of the multidrug resistance-1 gene in human pancreatic cancer: relevance to indicator of better prognosis. Jpn J Cancer Res 87: 641-649, 1996
9. Molnar J: New silicon compounds as resistance modifiers against multidrug-resistant cancer cells. Anticancer Res 24: 865-872, 2004.
10. Krishna R and Mayer LD: Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 11: 265-283, 2000.
11. Avendano C and Menendez JC: Inhibitors of multidrug resistance to antitumor agents (MDR). Curr Med Chem 9: 159-193, 2002.
12. Wang RB, Kuo CL, Lien LL and Lien EJ: Structure-activity relationship: analyses of P-glycoprotein substrates and inhibitors. J Clin Pharm Ther 28: 203-228, 2003.
13. Raderer M and Scheithauer W: Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer 72: 3553-3563, 1993.
14. Volm M: Multidrug resistance and its reversal. Anticancer Res 18: 2905-2917, 1998.
15. Thomas H and Coley HM: Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 10: 159-165, 2003.